{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:14:43Z","timestamp":1794280483878,"version":"4.9.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolving microneedles, offer several potential advantages over subcutaneous delivery. These include ease of administration, increased thermostability, an absence of sharps waste, reduced overall costs and pain-free administration. This trial will provide the first clinical trial data on MRV-MNP use and the first clinical vaccine trial of MNP technology in children and infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a phase 1\/2, randomized, active-controlled, double-blind, double-dummy, age de-escalation trial. Based on the defined eligibility criteria for the trial, including screening laboratory investigations, 45 adults [18\u201340 years] followed by 120 toddlers [15\u201318 months] and 120 infants [9\u201310 months] will be enrolled in series. To allow double-blinding, participants will receive either the MRV-MNP and a placebo (0.9% sodium chloride) subcutaneous (SC) injection or a placebo MNP and the MRV by SC injection (MRV-SC). Local and systemic adverse event data will be collected for 14 days following study product administration. Safety laboratories will be repeated on day 7 and, in the adult cohort alone, on day 14. Unsolicited adverse events including serious adverse events will be collected until the final study visit for each participant on day 180. Measles and rubella serum neutralizing antibodies will be measured at baseline, on day 42 and on day 180. Cohort progression will be dependent on review of the unblinded safety data by an independent data monitoring committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Pan-African Clinical Trials Registry\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=12234\">202008836432905<\/jats:ext-link>\n                      .\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04394689\">NCT04394689<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06493-5","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T10:05:02Z","timestamp":1663149902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Study protocol for a phase 1\/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-na\u00efve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1\/2 Age De-escalation Trial]"],"prefix":"10.1186","volume":"23","author":[{"given":"Ikechukwu","family":"Adigweme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edem","family":"Akpalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Yisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Donkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamin B.","family":"Jarju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baba","family":"Danso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulie","family":"Njie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Royals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Goodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-0340","authenticated-orcid":false,"given":"Ed","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"10111","key":"6493_CR1","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/S0140-6736(17)31463-0","volume":"390","author":"WJ Moss","year":"2017","unstructured":"Moss WJ. Measles. Lancet. 2017;390(10111):2490\u2013502.","journal-title":"Lancet"},{"issue":"6798","key":"6493_CR2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","volume":"406","author":"H Tatsuo","year":"2000","unstructured":"Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893\u20137.","journal-title":"Nature"},{"issue":"7378","key":"6493_CR3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature10639","volume":"480","author":"MD Muhlebach","year":"2011","unstructured":"Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature. 2011;480(7378):530\u20133.","journal-title":"Nature"},{"issue":"11","key":"6493_CR4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.1985.03350350068022","volume":"253","author":"PL Remington","year":"1985","unstructured":"Remington PL, Hall WN, Davis IH, Herald A, Gunn RA. Airborne transmission of measles in a physician's office. JAMA. 1985;253(11):1574\u20137.","journal-title":"JAMA"},{"issue":"4","key":"6493_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5365\/wpsar.2012.3.3.009","volume":"3","author":"K Hope","year":"2012","unstructured":"Hope K, Boyd R, Conaty S, Maywood P. Measles transmission in health care waiting rooms: implications for public health response. Western Pacific Surveill Response J. 2012;3(4):33\u20138.","journal-title":"Western Pacific Surveill Response J"},{"issue":"5","key":"6493_CR6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(09)70069-6","volume":"9","author":"J Lessler","year":"2009","unstructured":"Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291\u2013300.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"6493_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/096228029300200103","volume":"2","author":"K Dietz","year":"1993","unstructured":"Dietz K. The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res. 1993;2(1):23\u201341.","journal-title":"Stat Methods Med Res"},{"issue":"11","key":"6493_CR8","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1371\/journal.pmed.0020316","volume":"2","author":"J Wallinga","year":"2005","unstructured":"Wallinga J, Heijne JC, Kretzschmar M. A measles epidemic threshold in a highly vaccinated population. PLoS Med. 2005;2(11):e316.","journal-title":"PLoS Med"},{"issue":"6","key":"6493_CR9","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1128\/JVI.03029-12","volume":"87","author":"M Tahara","year":"2013","unstructured":"Tahara M, Ohno S, Sakai K, et al. The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope. J Virol. 2013;87(6):3583\u20136.","journal-title":"J Virol"},{"issue":"4","key":"6493_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/v8040112","volume":"8","author":"P Plattet","year":"2016","unstructured":"Plattet P, Alves L, Herren M, Aguilar HC. Measles virus fusion protein: structure, function and inhibition. Viruses. 2016;8(4):112.","journal-title":"Viruses"},{"issue":"9","key":"6493_CR11","first-page":"73","volume":"87","author":"WHO","year":"2012","unstructured":"WHO. Measles virus nomenclature update: 2012. Wkly Epidemiol Rec. 2012;87(9):73\u201381.","journal-title":"Wkly Epidemiol Rec"},{"issue":"4","key":"6493_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/v8040109","volume":"8","author":"SM Beaty","year":"2016","unstructured":"Beaty SM, Lee B. Constraints on the genetic and antigenic variability of measles virus. Viruses. 2016;8(4):109.","journal-title":"Viruses"},{"issue":"9","key":"6493_CR13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.celrep.2015.04.054","volume":"11","author":"BO Fulton","year":"2015","unstructured":"Fulton BO, Sachs D, Beaty SM, et al. Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. Cell Rep. 2015;11(9):1331\u20138.","journal-title":"Cell Rep"},{"issue":"5","key":"6493_CR14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1086\/422846","volume":"190","author":"SR Permar","year":"2004","unstructured":"Permar SR, Klumpp SA, Mansfield KG, et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis. 2004;190(5):998\u20131005.","journal-title":"J Infect Dis"},{"issue":"7","key":"6493_CR15","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1128\/JVI.77.7.4396-4400.2003","volume":"77","author":"SR Permar","year":"2003","unstructured":"Permar SR, Klumpp SA, Mansfield KG, et al. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol. 2003;77(7):4396\u2013400.","journal-title":"J Virol"},{"key":"6493_CR16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-065X.2010.00925.x","volume":"236","author":"DE Griffin","year":"2010","unstructured":"Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev. 2010;236:176\u201389.","journal-title":"Immunol Rev"},{"issue":"5","key":"6493_CR17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00006454-198705000-00007","volume":"6","author":"VG Tamashiro","year":"1987","unstructured":"Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J. 1987;6(5):451\u20134.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"6493_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/oxfordjournals.aje.a010267","volume":"151","author":"SM Akramuzzaman","year":"2000","unstructured":"Akramuzzaman SM, Cutts FT, Wheeler JG, Hossain MJ. Increased childhood morbidity after measles is short-term in urban Bangladesh. Am J Epidemiol. 2000;151(7):723\u201335.","journal-title":"Am J Epidemiol"},{"issue":"6465","key":"6493_CR19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aay6485","volume":"366","author":"MJ Mina","year":"2019","unstructured":"Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599\u2013606.","journal-title":"Science"},{"issue":"9","key":"6493_CR20","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2214-109X(15)00039-X","volume":"3","author":"GA Stevens","year":"2015","unstructured":"Stevens GA, Bennett JE, Hennocq Q, et al. Trends and mortality effects of vitamin a deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys. Lancet Glob Health. 2015;3(9):e528\u201336.","journal-title":"Lancet Glob Health"},{"issue":"45","key":"6493_CR21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.15585\/mmwr.mm7045a1","volume":"70","author":"MG Dixon","year":"2021","unstructured":"Dixon MG, Ferrari M, Antoni S, et al. Progress toward regional measles elimination - worldwide, 2000-2020. MMWR Morb Mortal Wkly Rep. 2021;70(45):1563\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"6493_CR22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ije\/dyn224","volume":"38","author":"LJ Wolfson","year":"2009","unstructured":"Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol. 2009;38(1):192\u2013205.","journal-title":"Int J Epidemiol"},{"key":"6493_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-3527(08)60328-0","volume":"44","author":"TK Frey","year":"1994","unstructured":"Frey TK. Molecular biology of rubella virus. Adv Virus Res. 1994;44:69\u2013160.","journal-title":"Adv Virus Res"},{"issue":"9984","key":"6493_CR24","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/S0140-6736(14)60539-0","volume":"385","author":"N Lambert","year":"2015","unstructured":"Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015;385(9984):2297\u2013307.","journal-title":"Lancet"},{"issue":"20","key":"6493_CR25","doi-asserted-by":"crossref","first-page":"11078","DOI":"10.1128\/JVI.01390-12","volume":"86","author":"AJ Battisti","year":"2012","unstructured":"Battisti AJ, Yoder JD, Plevka P, et al. Cryo-electron tomography of rubella virus. J Virol. 2012;86(20):11078\u201385.","journal-title":"J Virol"},{"issue":"Pt 2","key":"6493_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1099\/0022-1317-77-2-303","volume":"77","author":"R Petruzziello","year":"1996","unstructured":"Petruzziello R, Orsi N, Macchia S, Rieti S, Frey TK, Mastromarino P. Pathway of rubella virus infectious entry into Vero cells. J Gen Virol. 1996;77(Pt 2):303\u20138.","journal-title":"J Gen Virol"},{"issue":"3","key":"6493_CR27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/jcm.21.3.449-451.1985","volume":"21","author":"S Katow","year":"1985","unstructured":"Katow S, Sugiura A. Antibody response to individual rubella virus proteins in congenital and other rubella virus infections. J Clin Microbiol. 1985;21(3):449\u201351.","journal-title":"J Clin Microbiol"},{"issue":"1-2","key":"6493_CR28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01310962","volume":"83","author":"Y Umino","year":"1985","unstructured":"Umino Y, Sato TA, Katow S, Matsuno T, Sugiura A. Monoclonal antibodies directed to E1 glycoprotein of rubella virus. Arch Virol. 1985;83(1-2):33\u201342.","journal-title":"Arch Virol"},{"issue":"21","key":"6493_CR29","doi-asserted-by":"crossref","first-page":"11038","DOI":"10.1128\/JVI.05398-11","volume":"85","author":"H Cong","year":"2011","unstructured":"Cong H, Jiang Y, Tien P. Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus. J Virol. 2011;85(21):11038\u201347.","journal-title":"J Virol"},{"issue":"5","key":"6493_CR30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jnr.1173","volume":"65","author":"C Besson Duvanel","year":"2001","unstructured":"Besson Duvanel C, Honegger P, Matthieu JM. Antibodies directed against rubella virus induce demyelination in aggregating rat brain cell cultures. J Neurosci Res. 2001;65(5):446\u201354.","journal-title":"J Neurosci Res"},{"issue":"3","key":"6493_CR31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S0950268800004672","volume":"125","author":"WJ Edmunds","year":"2000","unstructured":"Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. Network EPES-e. the pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125(3):635\u201350.","journal-title":"Epidemiol Infect"},{"issue":"3","key":"6493_CR32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S0950268800004660","volume":"125","author":"WJ Edmunds","year":"2000","unstructured":"Edmunds WJ, van de Heijden OG, Eerola M, Gay NJ. Modelling rubella in Europe. Epidemiol Infect. 2000;125(3):617\u201334.","journal-title":"Epidemiol Infect"},{"issue":"3","key":"6493_CR33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0950268899003532","volume":"124","author":"FT Cutts","year":"2000","unstructured":"Cutts FT, Abebe A, Messele T, et al. Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia. Epidemiol Infect. 2000;124(3):467\u201379.","journal-title":"Epidemiol Infect"},{"key":"6493_CR34","first-page":"306","volume":"95","author":"WHO","year":"2020","unstructured":"WHO. Rubella vaccines: WHO position paper - July 2020. Weekly Epidemiol Record. 2020;95:306\u201324.","journal-title":"Weekly Epidemiol Record"},{"key":"6493_CR35","unstructured":"WHO. Global measles and rubella strategic plan 2012-2020."},{"issue":"6","key":"6493_CR36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1128\/CDLI.7.6.964-966.2000","volume":"7","author":"P Cordoba","year":"2000","unstructured":"Cordoba P, Lanoel A, Grutadauria S, Zapata M. Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status. Clin Diagn Lab Immunol. 2000;7(6):964\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"7","key":"6493_CR37","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1128\/jcm.30.7.1841-1847.1992","volume":"30","author":"LA Mitchell","year":"1992","unstructured":"Mitchell LA, Zhang T, Ho M, et al. Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay. J Clin Microbiol. 1992;30(7):1841\u20137.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"6493_CR38","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1128\/jcm.34.9.2210-2218.1996","volume":"34","author":"LA Mitchell","year":"1996","unstructured":"Mitchell LA, Ho MK, Rogers JE, et al. Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals. J Clin Microbiol. 1996;34(9):2210\u20138.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"6493_CR39","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/jcm.31.6.1521-1524.1993","volume":"31","author":"M Zrein","year":"1993","unstructured":"Zrein M, Joncas JH, Pedneault L, Robillard L, Dwyer RJ, Lacroix M. Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination. J Clin Microbiol. 1993;31(6):1521\u20134.","journal-title":"J Clin Microbiol"},{"issue":"8302","key":"6493_CR40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(82)92677-0","volume":"2","author":"E Miller","year":"1982","unstructured":"Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;2(8302):781\u20134.","journal-title":"Lancet"},{"issue":"1","key":"6493_CR41","first-page":"55","volume":"75","author":"FT Cutts","year":"1997","unstructured":"Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull World Health Organ. 1997;75(1):55\u201368.","journal-title":"Bull World Health Organ"},{"issue":"39","key":"6493_CR42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.15585\/mmwr.mm6839a5","volume":"68","author":"GB Grant","year":"2019","unstructured":"Grant GB, Desai S, Dumolard L, Kretsinger K, Reef SE. Progress toward rubella and congenital rubella syndrome control and elimination -worldwide, 2000-2018. MMWR Morb Mortal Wkly Rep. 2019;68(39):855\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6493_CR43","first-page":"205","volume":"17","author":"WHO","year":"2017","unstructured":"WHO. Measles vaccines: WHO position paper - April 2017. Wkly Epideiol Record. 2017;17:205\u201328.","journal-title":"Wkly Epideiol Record"},{"key":"6493_CR44","unstructured":"Rubella and congenital rubella syndrome control and elimination - global progress, 2012. Wkly Epidemiol Rec. 2013;88(49):521\u20137."},{"issue":"42","key":"6493_CR45","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.15585\/mmwr.mm6642a6","volume":"66","author":"A Dabbagh","year":"2017","unstructured":"Dabbagh A, Patel MK, Dumolard L, et al. Progress toward regional measles elimination - worldwide, 2000-2016. MMWR Morb Mortal Wkly Rep. 2017;66(42):1148\u201353.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"44","key":"6493_CR46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.15585\/mmwr.mm6444a4","volume":"64","author":"RT Perry","year":"2015","unstructured":"Perry RT, Murray JS, Gacic-Dobo M, et al. Progress toward regional measles elimination - worldwide, 2000-2014. MMWR Morb Mortal Wkly Rep. 2015;64(44):1246\u201351.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Supplement_4","key":"6493_CR47","doi-asserted-by":"crossref","first-page":"S420","DOI":"10.1093\/infdis\/jiaa793","volume":"224","author":"PA Gasta\u00f1aduy","year":"2021","unstructured":"Gasta\u00f1aduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. Measles in the 21st century: progress toward achieving and sustaining elimination. J Infect Dis. 2021;224(Supplement_4):S420\u2013S8.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"6493_CR48","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1016\/j.vaccine.2017.10.065","volume":"36","author":"WA Orenstein","year":"2018","unstructured":"Orenstein WA, Cairns L, Hinman A, Nkowane B, Olive JM, Reingold AL. Measles and rubella global strategic plan 2012-2020 midterm review report: background and summary. Vaccine. 2018;36(Suppl 1):A35\u201342.","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"6493_CR49","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.vaccine.2017.09.026","volume":"36","author":"WA Orenstein","year":"2018","unstructured":"Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and rubella global strategic plan 2012-2020 midterm review. Vaccine. 2018;36(Suppl 1):A1\u2013A34.","journal-title":"Vaccine"},{"key":"6493_CR50","volume-title":"Immunization agenda 2030 (IA2030)","author":"Organization WH","year":"2020","unstructured":"Organization WH. Immunization agenda 2030 (IA2030). Geneva: World Health Organization. http:\/\/www.immunizationagenda2030.org\/; 2020."},{"key":"6493_CR51","unstructured":"WHO. Measles and rubella strategic framework: 2021-2030. https:\/\/www.whoint\/publications\/i\/item\/measles-and-rubella-strategic-framework-2021-2030 Accessed 5 Oct 2021 2020."},{"key":"6493_CR52","unstructured":"Gavi t VA. Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan. https:\/\/www.gavi.org\/sites\/default\/files\/about\/market-shaping\/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf 2021."},{"key":"6493_CR53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2015.11.019","volume":"240","author":"J Arya","year":"2016","unstructured":"Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Contr Release. 2016;240:135\u201341.","journal-title":"J Contr Release"},{"issue":"34","key":"6493_CR54","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1016\/j.vaccine.2012.09.062","volume":"31","author":"C Edens","year":"2013","unstructured":"Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine. 2013;31(34):3403\u20139.","journal-title":"Vaccine"},{"issue":"37","key":"6493_CR55","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1016\/j.vaccine.2015.02.074","volume":"33","author":"C Edens","year":"2015","unstructured":"Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015;33(37):4712\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"6493_CR56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/infdis\/jiy139","volume":"218","author":"JC Joyce","year":"2018","unstructured":"Joyce JC, Carroll TD, Collins ML, et al. A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques. J Infect Dis. 2018;218(1):124\u201332.","journal-title":"J Infect Dis"},{"issue":"10095","key":"6493_CR57","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","volume":"390","author":"NG Rouphael","year":"2017","unstructured":"Rouphael NG, Paine M, Mosley R, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017;390(10095):649\u201358.","journal-title":"Lancet"},{"key":"6493_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.02.040","volume":"128","author":"J Arya","year":"2017","unstructured":"Arya J, Henry S, Kalluri H, McAllister DV, Pewin WP, Prausnitz MR. Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects. Biomaterials. 2017;128:1\u20137.","journal-title":"Biomaterials"},{"issue":"3","key":"6493_CR59","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S2214-109X(20)30481-2","volume":"9","author":"O Wariri","year":"2021","unstructured":"Wariri O, Nkereuwem E, Erondu NA, et al. A scorecard of progress towards measles elimination in 15 west African countries, 2001-19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data. Lancet Glob Health. 2021;9(3):e280\u2013e90.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"6493_CR60","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","volume":"4","author":"E Clarke","year":"2016","unstructured":"Clarke E, Saidu Y, Adetifa JU, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in the Gambia. Lancet Glob Health. 2016;4(8):e534\u201347.","journal-title":"Lancet Glob Health"},{"key":"6493_CR61","unstructured":"UNICEF. Senegal Multiple Cluster Indicator Survey 2016. 2016. https:\/\/mics.unicef.org\/ (Accessed 19 May 2020)."},{"issue":"12","key":"6493_CR62","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1017\/S0950268812000131","volume":"140","author":"CJ Metcalf","year":"2012","unstructured":"Metcalf CJ, Lessler J, Klepac P, Cutts F, Grenfell BT. Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination. Epidemiol Infect. 2012;140(12):2290\u2013301.","journal-title":"Epidemiol Infect"},{"issue":"12","key":"6493_CR63","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2471\/BLT.17.195735","volume":"95","author":"A Auta","year":"2017","unstructured":"Auta A, Adewuyi EO, Tor-Anyiin A, et al. Health-care workers\u2019 occupational exposures to body fluids in 21 countries in Africa: systematic review and meta-analysis. Bull World Health Organ. 2017;95(12):831\u201341F.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"6493_CR64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5334\/aogh.2698","volume":"86","author":"S Bouya","year":"2020","unstructured":"Bouya S, Balouchi A, Rafiemanesh H, et al. Global prevalence and device related causes of needle stick injuries among health care workers: a systematic review and meta-analysis. Ann Glob Health. 2020;86(1):35.","journal-title":"Ann Glob Health"},{"issue":"4","key":"6493_CR65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40268-016-0144-x","volume":"16","author":"BB Adhikari","year":"2016","unstructured":"Adhikari BB, Goodson JL, Chu SY, Rota PA, Meltzer MI. Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: the case for further research and development. Drugs R D. 2016;16(4):327\u201338.","journal-title":"Drugs R D"},{"issue":"41","key":"6493_CR66","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1016\/j.vaccine.2016.07.021","volume":"34","author":"OT Idoko","year":"2016","unstructured":"Idoko OT, Hampton LM, Mboizi RB, et al. Acceptance of multiple injectable vaccines in a single immunization visit in the Gambia pre and post introduction of inactivated polio vaccine. Vaccine. 2016;34(41):5034\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"6493_CR67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","volume":"26","author":"BJ Cohen","year":"2007","unstructured":"Cohen BJ, Audet S, Andrews N, Beeler J, test WHOwgomprn. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007;26(1):59\u201366.","journal-title":"Vaccine"},{"issue":"50","key":"6493_CR68","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1016\/j.vaccine.2014.09.071","volume":"32","author":"S Cape","year":"2014","unstructured":"Cape S, Chaudhari A, Vaidya V, et al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled phase I clinical trial. Vaccine. 2014;32(50):6791\u20137.","journal-title":"Vaccine"},{"issue":"1-2","key":"6493_CR69","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jviromet.2007.08.021","volume":"146","author":"MH Chen","year":"2007","unstructured":"Chen MH, Zhu Z, Zhang Y, et al. An indirect immunocolorimetric assay to detect rubella virus infected cells. J Virol Methods. 2007;146(1-2):414\u20138.","journal-title":"J Virol Methods"},{"issue":"3","key":"6493_CR70","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/CVI.05537-11","volume":"19","author":"GP Smits","year":"2012","unstructured":"Smits GP, van Gageldonk PG, Schouls LM, van der Klis FR, Berbers GA. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clin Vaccine Immunol. 2012;19(3):396\u2013400.","journal-title":"Clin Vaccine Immunol"},{"key":"6493_CR71","unstructured":"WHO International Standard, 3rd International Standard for Anti-Measles; NIBSC code: 97\/648; Instructions for Use (Version 2.0, Dated 26\/02\/2008). https:\/\/www.nibsc.org\/documents\/ifu\/97-648.pdf. Accessed 1 July 2021."},{"key":"6493_CR72","unstructured":"WHO International Standard; Anti rubella immunoglobulin, human; NIBSC code: RUBI-1-94; Instructions for use; (Version 8.0, Dated 11\/03\/2019)."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06493-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T09:39:08Z","timestamp":1664962748000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06493-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6493"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06493-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial requires the approval of The Gambia Government\/MRC Joint Ethics Committee and the LSHTM Research Ethics Committee (reference LEO 22420). Regulatory approval is required from the Gambian Medicines Control Agency which is the national regulatory agency in The Gambia. Written or thumb-printed informed consent for study participation will be obtained from all participants\/the parents of study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"A copy of the informed consent documents for the trial may be made available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"SH, MRP, DM and MR are employees or consultants of Micron Biomedical, Inc \u2014 the developers of the MRV-MNP. No other authors declare any conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"775"}}